Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs

Lancet

Volumn 370, Issue 9604, 2007, Pages 2054-2062

  Lim, Stephen S ^a,b   Gaziano, Thomas A ^c   Gakidou, Emmanuela ^a,b   Reddy, K Srinath ^d,e   Farzadfar, Farshad ^f   Lozano, Rafael ^g   Rodgers, Anthony ^h  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d PUBLIC HEALTH FOUNDATION OF INDIA   (India)

^e ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^g Ministry of Health   (Mexico)

^h University of Auckland Clinical Trials Research Unit   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; STATIN;

ADULT; AGED; CARDIOVASCULAR DISEASE; FEMALE; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 36549025835     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)61699-7     Document Type: Review

References (60)

1. Strong K., Mathers C., Leeder S., and Beaglehole R. Preventing chronic diseases: how many lives can we save?. Lancet 366 (2005) 1578-1582
2. Mathers C., and Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3 (2006) e442
3. Omran A. The epidemiologic transition: a theory of the epidemiology of population change. Milbank Memorial Fund Quarterly 49 (1971) 509-538
4. Lopez A., Mathers C., Ezzati M., Jamison D., and Murray C. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 367 (2006) 1714-1757
5. Ezzati M., Vander Hoorn S., Lawes C., et al. Rethinking the "Diseases of Affluence" paradigm: global patterns of nutritional risks in relation to economic development. PLoS Med 2 (2005) e133
6. Murray C., Lauer J., Hutubessy R., et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet 361 (2003) 717-725
7. Shibuya K., Ciecierski C., Guindon E., Bettcher D., Evans D., and Murray C. WHO Framework Convention on Tobacco Control: development of an evidence based global public health treaty. BMJ 327 (2003) 154-157
8. WHO. World Health Report 2002 (2002), World Health Organization, Geneva
9. Gaziano T., Opie L., and Weinstein M. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet 368 (2006) 679-686
10. Gaziano T., Galea G., and Reddy K. Scaling up interventions for chronic disease prevention: the evidence. Lancet (2007). published online Dec 5. DOI:10.1016/S0140-6736(07)61697-3
11. Asaria P., Chisholm D., Mathers C., Ezzati M., and Beaglehole R. Chronic disease prevention: health effects and financial costs of strategies to reduce salt intake and control tobacco use. Lancet (2007). published online Dec 5. DOI:10.1016/S0140-6736(07)61698-5
12. Wald N., Law M., Morris J., and Jordan R. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 326 (2003) 1427-1431
13. Blood Pressure Lowering Treatment Trialist's Collaboration. Effect of different blood-pressure lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362 (2003) 1527-1535
14. Law M., Wald N., and Rudnicka A. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease and stroke: systematic review and meta-analysis. BMJ 2003 (2003) 1423-1427
15. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ 324 (2002) 71-86
16. Mendis S., Abegunde D., Yusuf S., et al. WHO Study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE). Bull World Health Organ 83 (2005) 820-828
17. Jackson R., Lawes C., Bennett D., Milne R., and Rodgers A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet 365 (2005) 434-441
18. Murray C., Lauer J., Hutubessy R., et al. Effectiveness and costs of interventions to lower blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular disease risk. Lancet 361 (2003) 717-725
19. Wald N., and Law M. A strategy to reduce cardiovascular disease by more than 80%. BMJ 326 (2003) 1419
20. Yusuf S. Two decades of progress in preventing vascular disease. Lancet 360 (2002) 2-3
21. Reddy K. The preventive polypill-much promise, insufficient evidence. N Engl J Med 356 (2007) 212
22. Johns B., Sigurbjornsdottir K., Fogstad H., Zupan J., Mathai M., and Edejer T.T.-T. Estimated global resources needed to attain universal coverage of maternal and newborn health services. Bull World Health Organ 85 (2007) 256-263
23. Stenberg K., Johns B., Scherpbier R., and Edejer T.T.-T. A financial road map to scaling up essential child health interventions in 75 countries. Bull World Health Organ 85 (2007) 305-314
24. Williams B. Evolution of hypertensive disease: a revolution in guidelines. Lancet 368 (2006) 6-8
25. World Health Organization. WHO Global InfoBase. http://www.who.int/ncd_surveillance/infobase/web/InfoBaseCommon/ (accessed Feb 6, 2007).
26. Lawes C., Vander Hoorn S., Law M., Elliott P., MacMahon S., and Rodgers A. Chapter 6: High blood pressure. In: Ezzati M., Lopez A., Rodgers A., and Murray C. (Eds). Comparative quantification of health risks (2004), World Health Organization, Geneva
27. Lawes C., Vander Hoorn S., Law M., and Rodgers A. Chapter 7: High cholesterol. In: Ezzati M., Lopez A., Rodgers A., and Murray C. (Eds). Comparative quantification of health risks (2004), World Health Organization, Geneva
28. Ezzati M., and Lopez A. Chapter 11: Smoking and oral tobacco use. In: Ezzati M., Lopez A., Rodgers A., and Murray C. (Eds). Comparative quantification of health risks (2004), World Health Organization, Geneva 883-958
29. Huxley R., Barzi F., and Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 332 (2006) 73-78
30. Asia Pacific Cohort Studies Collaboration. The effects of diabetes on the risks of major cardiovascular diseases and death in the Asia-Pacific region. Diabetes Care 26 (2003) 360-366
31. Bronnum-Hansen H., Jorgensen T., Davidsen M., et al. Survival and cause of death after myocardial infarction: the Danish MONICA study. J Clin Epidemiol 54 (2001) 1244-1250
32. Bronnum-Hansen H., Davidsen M., Thorvaldsen P., and Danish M. Long-term survival and causes of death after stroke. Stroke 32 (2001) 2131-2136
33. Anderson K., Odell P., Wilson P., and Kannel W. Cardiovascular disease risk profiles. Am Heart J 121 (1991) 293-298
34. WHO. Health and the Millennium Development Goals (2005), World Health Organization, Geneva
35. Ranson M., Hanson K., Oliveira-Cruz V., and Mills A. Constraints to expanding access to health interventions: an empirical analysis and country typology. J Int Development 15 (2003) 15-39
36. World Health Organization. World Health Survey Results: Country Reports. http://www.who.int/healthinfo/survey/whsresults/en/index.html (accessed Feb 17, 2007).
37. Freemantle N., Cleland J., Young P., Mason J., and Harrison J. Beta-blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 318 (1999) 1730-1737
38. Yusuf S., Wittes J., and Friedman L. Overview of results of randomized clinical trials in heart disease I. Treatments following myocardial infarction. JAMA 260 (1998) 2088-2093
39. Evans D., Edejer T.T.-T., Adam T., and Lim S. Methods to assess the costs and health effects of interventions for improving health in developing countries. BMJ 331 (2005) 1137-1140
40. Jackevicius C., Mamdani M., and Tu J. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 288 (2002) 462-467
41. Ellis J., Erickson S., Stevenson J., Bernstein S., Stiles R., and Fendrick A. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations: should we target patients with the most to gain?. J Gen Inter Med 19 (2004) 638-645
42. Kopjar B., Sales A., Piñeros S., Sun H., Li Y.-F., and Hedeen A. Adherence with statin therapy in secondary prevention of coronary heart disease in veterans administration male population. Am J Cardiol 92 (2003) 1106-1108
43. Benner J., Glynn R., Mogun H., Neumann P., Weinstein M., and Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA 288 (2002) 455-461
44. Gislason G., Rasmussen J., Abildstrøm S., et al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J 27 (2006) 1153-1158
45. Newby L., LaPointe N.A., Chen A., et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 113 (2006) 203-212
46. Mantel-Teeuwisse A., Goettsch W., Klungel O., de Boer A., and Herings R. Long term persistence with statin treatment in daily medical practice. Heart 90 (2004) 1065-1066
47. Bovet P., Burner M., and Madeleine G. Monitoring one-year compliance to antihypertension medication in the Seychelles. Bull World Health Organ 80 (2002) 33-39
48. Management Sciences for Health. International Drug Price Indicator. http://erc.msh.org/mainpage.cfm?file=1.0.htm&module=DMP&language =english (accessed Feb 6, 2007).
49. World Health Organization. CHOosing Interventions that are Cost Effective (WHO-CHOICE): country specific costs. http://www.who.int/choice/country/en/index.html (accessed Feb 15, 2007).
50. Gutierrez J., Johns B., Adam T., et al. Achieving the WHO/UNAIDS antiretroviral treatment 3 by 5 goal: what will it cost?. Lancet 364 (2004) 63-64
51. Bryce J., Black R., Walker N., Bhutta Z., Lawn J., and Steketee R. Can the world afford to save the lives of 6 million children each year?. Lancet 365 (2005) 2193-2200
52. Martines J., Paul V., Bhutta Z., et al. Neonatal survival: a call for action. Lancet 365 (2005) 1189-1197
53. UNAIDS. Resource needs for an expanded response to AIDS in low- and middle-income countries: UNAIDS, 2005.
54. WHO. The Global Plan to Stop TB, 2006-2015; methods used to estimate costs, funding and funding gaps (2006), World Health Organization, Geneva
55. Mendis S., Fukino K., Cameron A., et al. The availability and affordability of selected essential medicines for chronic disease in six low- and middle-income countries. Bull World Health Organ 58 (2007) 279-288
56. Abegunde D., Shengelia B., Luyten A., et al. Can non-physician health-care workers assess and manage cardiovascular risk in primary care?. BullWorld Health Organ 85 (2007) 432-440
57. Schedlbauer A., Schroeder K., Peters T., and Fahey T. Interventions to improve adherence to lipid lowering medication. Cochrane Database Syst Rev 4 (2004). CD004371. DOI: 10.1002/14651858.CD004371.pub2
58. Schroeder K., Fahey T., and Ebrahim S. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Database Syst Rev 3 (2004). CD004804. DOI: 10.1002/14651858.CD004804
59. Victora C., Hanson K., Bryce J., and Vaughan J. Achieving universal coverage with health interventions. Lancet 364 (2004) 1541-1548
60. Egger M., Boulle A., Schechter M., and Miotti P. Antiretroviral therapy in resource poor settings: scaling up inequalities. Int J Epidemiol 34 (2005) 509-512